Brandicourt’s Message To Sanofi Investors: Grow, Build, Explore Options
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Olivier Brandicourt's multi-pronged strategy involves defending in core areas like diabetes, vaccines and rare diseases, building in consumer healthcare, oncology and multiple sclerosis and reviewing strategic alternatives in other areas, including animal health.
You may also be interested in...
Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.